Carl Harald Janson has decided to step back from his role as International Biotechnology Trust's lead investment manager but will remain as a senior adviser to SV Health Investors.
Lead responsibility for portfolio management will be handed to Ailsa Craig and Marek Poszepczynski, following a handover period with Janson, who led the trust for seven years. Kate Bingham will remain the Investment Manager of the Company's unquoted portfolio. Investing in biotech: Where are we now and what is the outlook? Jim Horsburgh, chair, said: "We thank Carl Harald for the pivotal role he has played over the past seven years leading International Biotechnology Trust to an all-time high in NAV terms in 2020, and wish him well for the future. Ailsa and Marek are extremely capa...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
